Browsing by Author "Méndez-Vidal, María José"

Sort by: Order: Results:

  • Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
    Climent, Miguel Ángel; Álvarez, Carlos; Morales-Barrera, Rafael; Maroto, Pablo; Rodríguez-Vida, Alejo; Méndez-Vidal, María José; García del Muro, Xavier; Puente, Javier; Láinez, Nuria; Vázquez, Sergio; Castellano, Daniel; Gómez Lang, Carmen; Wang, Jing; Di Pietro, Alessandra; Davis, Craig; Sanz Castillo, Belén; Bolós, M. Victoria; Valderrama, Begoña P. (Springer, 2024)
    Purpose: Post hoc analysis of the JAVELIN Bladder 100 trial of avelumab maintenance in locally advanced/metastatic urothelial carcinoma (la/mUC) to determine the interaction by programmed death ligand 1 (PD-L1) status for ...
  • Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
    Méndez-Vidal, María José; Molina, Áurea; Anido, Urbano; Chirivella, Isabel; Etxaniz, Olatz; Fernández-Parra, Eva; Guix Arnau, Marta, 1974-; Hernández, Carolina; Lambea, Julio; Montesa, Álvaro; Pinto, Álvaro; Ros, Silverio; Gallardo, Enrique (BioMed Central, 2018)
    BACKGROUND: Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking